Mesirow Financial Investment Management’s Health Catalyst HCAT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q2
Sell
-9,018
Closed -$236K 76
2022
Q1
$236K Buy
9,018
+22
+0.2% +$624 0.8% 73
2021
Q4
$356K Hold
8,996
1.03% 58
2021
Q3
$450K Sell
8,996
-282
-3% -$15.4K 1.32% 40
2021
Q2
$515K Buy
9,278
+32
+0.3% +$1.71K 1.32% 33
2021
Q1
$432K Sell
9,246
-303
-3% -$14.7K 1.17% 48
2020
Q4
$416K Buy
9,549
+39
+0.4% +$1.44K 1.31% 33
2020
Q3
$348K Buy
9,510
+1,461
+18% +$49.6K 1.49% 24
2020
Q2
$235K Buy
+8,049
New +$222K 1.11% 59

Other funds holding HCAT

Mesirow Financial Investment Management's HCAT Position: Q2 2022 in Review

Mesirow Financial Investment Management sold out of Health Catalyst (HCAT) in Q2 2022, closing a stake of 9,018 shares — an estimated $236K sold.

Mesirow Financial Investment Management first reported a position in HCAT in Q2 2020 and held it in 8 quarters. The position peaked at $515K in Q2 2021. 180 funds tracked by Wall St. Rank hold HCAT as of Q2 2022.

  • Mesirow Financial Investment Management reported no remaining Health Catalyst position as of Q2 2022 after selling out during the quarter.
  • Mesirow Financial Investment Management sold 9,018 Health Catalyst shares in Q2 2022, an estimated $236K.
  • Mesirow Financial Investment Management first reported a position in Health Catalyst in Q2 2020 and held it in 8 quarters.
  • Mesirow Financial Investment Management's Health Catalyst position peaked at $515K in Q2 2021.
  • 180 funds tracked by Wall St. Rank held Health Catalyst as of Q2 2022.

Based on Mesirow Financial Investment Management's 13F filing for Q2 2022, filed 20 Jul 2022.